Both medications embody a innovative class of antibody interventions designed to block the COVID-19 pathogen . Initially , sotrovimab, created by the companies, demonstrated substantial benefit against https://finnianukna498384.blognody.com/51310851/sotrovimab-vir-7831-a-deep-investigation-into-the-immunoglobulin-therapy